# Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension

> **NCT05437224** · PHASE3 · COMPLETED · sponsor: **RenJi Hospital** · enrollment: 80 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Ambrisentan

## Key facts

- **NCT ID:** NCT05437224
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-18
- **Primary completion:** 2022-01-09
- **Final completion:** 2022-02-06
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2022-06-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05437224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05437224, "Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05437224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*